PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33978073-5 2021 RESULTS: Data showed a reduction in malondialdehyde (MDA), myeloperoxidase (MPO), and TNF-alpha in the animals pretreated with NAC or MEL when compared to those treated with SS+iIR (p<0.05). Acetylcysteine 127-130 myeloperoxidase Rattus norvegicus 59-74 33978073-5 2021 RESULTS: Data showed a reduction in malondialdehyde (MDA), myeloperoxidase (MPO), and TNF-alpha in the animals pretreated with NAC or MEL when compared to those treated with SS+iIR (p<0.05). Acetylcysteine 127-130 myeloperoxidase Rattus norvegicus 76-79 31594390-4 2020 AuNP + NAC association decreased MPO activity and pro-inflammatory cytokines production, being more effective than NAC or AuNP isolated treatment. Acetylcysteine 7-10 myeloperoxidase Rattus norvegicus 33-36 26680088-6 2015 RESULTS: NAC, ATOR, and NAC+ATOR in rats showed lower MPO (P < .05) and higher GPx activity (P < .05) versus control; SOD activity was lower in NAC versus ATOR (P < .05). Acetylcysteine 9-12 myeloperoxidase Rattus norvegicus 54-57 31838118-11 2020 Furthermore, NAC improved redox and inflammatory status; decreased levels of RIPK3, MLKL, NLRP3, IL-18; down-regulated ASC, iNOS, GFAP and MMP-9 expression; and decreased myeloperoxidase activity in cerebral cortex. Acetylcysteine 13-16 myeloperoxidase Rattus norvegicus 171-186 31655538-14 2019 Interestingly, NAC elevated MPO and HMGB-1 levels significantly. Acetylcysteine 15-18 myeloperoxidase Rattus norvegicus 28-31 27717985-8 2017 TQ or NAC pretreatment significantly decreased elevated serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and myeloperoxidase (MPO) activities, malondialdehyde (MDA) level, and NO production. Acetylcysteine 6-9 myeloperoxidase Rattus norvegicus 132-147 27717985-8 2017 TQ or NAC pretreatment significantly decreased elevated serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and myeloperoxidase (MPO) activities, malondialdehyde (MDA) level, and NO production. Acetylcysteine 6-9 myeloperoxidase Rattus norvegicus 149-152 27083693-5 2016 Both NAC and enoxaparin led to a significant reduction in ovarian tissue 8-OHdG (P = 0.004 and P = 0.01, respectively) and MPO (P = 0.013 and P = 0.023, respectively) concentrations compared with I/R group, indicating a protective effect against I/R oxidative damage. Acetylcysteine 5-8 myeloperoxidase Rattus norvegicus 123-126 25941092-11 2016 Only MPO activity increased in both IND and NAC groups when compared to healthy rat group. Acetylcysteine 44-47 myeloperoxidase Rattus norvegicus 5-8 27957238-6 2016 NAC led to a decrease in hydrogen peroxide (H2O2), malondialdehyde (MDA) levels, and myeloperoxidase activity. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 85-100 26680088-6 2015 RESULTS: NAC, ATOR, and NAC+ATOR in rats showed lower MPO (P < .05) and higher GPx activity (P < .05) versus control; SOD activity was lower in NAC versus ATOR (P < .05). Acetylcysteine 24-27 myeloperoxidase Rattus norvegicus 54-57 26680088-6 2015 RESULTS: NAC, ATOR, and NAC+ATOR in rats showed lower MPO (P < .05) and higher GPx activity (P < .05) versus control; SOD activity was lower in NAC versus ATOR (P < .05). Acetylcysteine 24-27 myeloperoxidase Rattus norvegicus 54-57 25724285-7 2015 Pre-treatment of EUK-134 or NAC alone altered the level of total free radical generation, LPO, GSH content and catalytic activity of MPO, SOD, GR and GPx and the expression of metallothionein I and II towards normalcy. Acetylcysteine 28-31 myeloperoxidase Rattus norvegicus 133-136 23475548-7 2013 RESULTS: Serum transaminases and tissue and serum MDA and tissue MPO were all increased in group 1 compared to control and were significantly decreased in the group treated with NAC. Acetylcysteine 178-181 myeloperoxidase Rattus norvegicus 65-68 24872935-8 2014 Hepatic malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO) activities were significantly increased after I/R injury, but they were decreased in the groups with NAC treatment. Acetylcysteine 177-180 myeloperoxidase Rattus norvegicus 31-46 24872935-8 2014 Hepatic malondialdehyde (MDA), myeloperoxidase (MPO), and nitric oxide (NO) activities were significantly increased after I/R injury, but they were decreased in the groups with NAC treatment. Acetylcysteine 177-180 myeloperoxidase Rattus norvegicus 48-51 22336129-10 2012 The administration of NAC increased GSH, attenuated ROS, cytokines, MPO, JNK, pAKT and caspase-3 and lung permeability associated with decreased activation of nuclear factor-kappaB. Acetylcysteine 22-25 myeloperoxidase Rattus norvegicus 68-71 19122686-6 2008 Tissue MPO activities of R+NAC and R+WR-2721 rats were higher than those of R rats (p<0.001). Acetylcysteine 27-30 myeloperoxidase Rattus norvegicus 7-10 20673252-10 2012 The content of muscle-derived ROS, TBARS, EBD and MPO activity in both gastrocnemius and soleus muscles were also decreased by NAC pre-treatment. Acetylcysteine 127-130 myeloperoxidase Rattus norvegicus 50-53 22453841-10 2012 NAC reduced lung MPO activity in mild but not in severe AP. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 17-20 23101021-12 2012 The activity of MPO in NAC treatment group was significantly lower than that of LPS group (6.4+-1.8 unit/g vs. 11.2+-6.3 unit/g, tissue) (p<0.048). Acetylcysteine 23-26 myeloperoxidase Rattus norvegicus 16-19 17046137-10 2006 Posttreatment with erdosteine and NAC significantly reduced the increases in the local production of TNF-alpha and VEGF, and epithelial MPO activity. Acetylcysteine 34-37 myeloperoxidase Rattus norvegicus 136-139 18642776-14 2008 The intrapancreatic MPO levels at the time points 3 h, 6 h, and 12 h of the NAC group were 0.63 +/- 0.03, 0.88 +/- 0.05, and 1.31 +/- 0.09 respectively, all significantly lower than those of the ANP groups (0.89 +/- 0.03, 1.42 +/- 0.14, and 1.94 +/- 0.07, all P < 0.05). Acetylcysteine 76-79 myeloperoxidase Rattus norvegicus 20-23 17884964-8 2007 NAC and vitamin E significantly reduced the increases in the local production of TNF-alpha and VEGF, and perivascular MPO activity. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 118-121 17216608-10 2007 Erdosteine, NAC and vitamin E significantly reduced the increases in the local production of TNF-alpha and heart MPO activity. Acetylcysteine 12-15 myeloperoxidase Rattus norvegicus 113-116 16489261-1 2005 The aim of the present study was to evaluate the effects of N-acetylcysteine (NAC) and L-carnitine (LCAR) supplementations on polymorphonuclear leukocytes myeloperoxidase (MPO) and Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and plasma malondialdehyde (MDA) in acetic acid (AA)-induced ulcerative colitis model. Acetylcysteine 60-76 myeloperoxidase Rattus norvegicus 155-170 16369183-8 2006 NAC administration increased the ReGSH (P = 0.036) and decreased the MDA, MPO, and NN (P = 0.008, P = 0.01, P = 0.032, respectively), compared with the CLP group. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 74-77 16489261-3 2005 Both NAC and LCAR pretreatment markedly decreased MPO and Cu/Zn-SOD activity compared to colitis group. Acetylcysteine 5-8 myeloperoxidase Rattus norvegicus 50-53 16377052-10 2006 Erdosteine, NAC, and vitamin E significantly reduced the increases in TNF-alpha staining and lung MPO activity. Acetylcysteine 12-15 myeloperoxidase Rattus norvegicus 98-101 16489261-1 2005 The aim of the present study was to evaluate the effects of N-acetylcysteine (NAC) and L-carnitine (LCAR) supplementations on polymorphonuclear leukocytes myeloperoxidase (MPO) and Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and plasma malondialdehyde (MDA) in acetic acid (AA)-induced ulcerative colitis model. Acetylcysteine 78-81 myeloperoxidase Rattus norvegicus 155-170 16489261-1 2005 The aim of the present study was to evaluate the effects of N-acetylcysteine (NAC) and L-carnitine (LCAR) supplementations on polymorphonuclear leukocytes myeloperoxidase (MPO) and Cu/Zn-superoxide dismutase (Cu/Zn-SOD) and plasma malondialdehyde (MDA) in acetic acid (AA)-induced ulcerative colitis model. Acetylcysteine 78-81 myeloperoxidase Rattus norvegicus 172-175 12684259-4 2003 Rats receiving N-acetylcysteine (300 mg kg(-1) day(-1), intraperitoneal) had less augmented lung wet weight, and lower levels of proteins, lactate dehydrogenase, neutrophil and macrophage counts in bronchoalveolar lavage fluid and lung myeloperoxidase activity with a betterment of histological score at 3 days postbleomycin. Acetylcysteine 15-31 myeloperoxidase Rattus norvegicus 236-251 16088183-3 2005 The use of NAC inhibited the changes in urine output, pO(2), tissue activity of MPO and MDA in pancreas and lungs, and the serum activity of IL-6, ALT, and serum concentrations of urea and calcium. Acetylcysteine 11-14 myeloperoxidase Rattus norvegicus 80-83 15790131-5 2005 Treatment with 100 mg/kg NAC for 7 days significantly decreased tissue myeloperoxidase, glutathione and nitric oxide concentrations. Acetylcysteine 25-28 myeloperoxidase Rattus norvegicus 71-86 15841722-8 2005 Pretreatment with NAC, PDTC, PD98059 or Genistein significantly decreased MPO levels in the pancreas at 3 and 6 h and following the administration of PD-98059 or NAC at 6 h. Pretreatment with NAC significantly decreased MPO levels in the lungs at 3 h. CONCLUSIONS: Pretreatment with NAC could regulate the pro-and anti-inflammatory cytokine balance, probably through NF-kappaB and ROS signaling pathways. Acetylcysteine 18-21 myeloperoxidase Rattus norvegicus 74-77 15841722-8 2005 Pretreatment with NAC, PDTC, PD98059 or Genistein significantly decreased MPO levels in the pancreas at 3 and 6 h and following the administration of PD-98059 or NAC at 6 h. Pretreatment with NAC significantly decreased MPO levels in the lungs at 3 h. CONCLUSIONS: Pretreatment with NAC could regulate the pro-and anti-inflammatory cytokine balance, probably through NF-kappaB and ROS signaling pathways. Acetylcysteine 18-21 myeloperoxidase Rattus norvegicus 220-223 14680076-6 2003 The bleomycin-induced increases in lung tumour necrosis factor-alpha and myeloperoxidase activity were reduced by NAC treatment. Acetylcysteine 114-117 myeloperoxidase Rattus norvegicus 73-88 16243047-13 2005 There was significant decrease at serum and lung MPO and MDA levels after the NAC application in groups D and E, when compared with group C (P = 0.0001, for each comparison). Acetylcysteine 78-81 myeloperoxidase Rattus norvegicus 49-52 15555789-11 2004 Treatment of rats with NAC significantly elevated the reduced GSH levels while decreasing MDA levels and MPO activity. Acetylcysteine 23-26 myeloperoxidase Rattus norvegicus 105-108 12460510-4 2002 RESULTS: Postinjury WBC in BALF, MPO activity in pulmonary tissue and H(2)O(2) content decreased obviously after NAC treatment. Acetylcysteine 113-116 myeloperoxidase Rattus norvegicus 33-36 11707313-2 2000 (2) Depending on the dose used, NAC administered intracolonically was found to reduce the extent of colonic damage, along with a decrease in myeloperoxidase (MPO) activity, colonic wet weight and wet/dry weight ratio. Acetylcysteine 32-35 myeloperoxidase Rattus norvegicus 141-156 10963726-4 2000 NAC also attenuated the ileum injury (histology) as well as the increase in the tissue levels of myeloperoxidase (MPO) and malondialdehyde (MDA) caused by SAO shock in the ileum. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 97-112 10963726-4 2000 NAC also attenuated the ileum injury (histology) as well as the increase in the tissue levels of myeloperoxidase (MPO) and malondialdehyde (MDA) caused by SAO shock in the ileum. Acetylcysteine 0-3 myeloperoxidase Rattus norvegicus 114-117 11707313-2 2000 (2) Depending on the dose used, NAC administered intracolonically was found to reduce the extent of colonic damage, along with a decrease in myeloperoxidase (MPO) activity, colonic wet weight and wet/dry weight ratio. Acetylcysteine 32-35 myeloperoxidase Rattus norvegicus 158-161 10470760-16 1999 In addition, ip administration of N-acetylcysteine (40 mg/kg, 1 and 6 hrs after zymosan) was effective in preventing the development of lung and intestine injury and neutrophil infiltration, as determined by myeloperoxidase evaluation. Acetylcysteine 34-50 myeloperoxidase Rattus norvegicus 208-223 10923013-10 2000 RESULTS: At the early time point, both NAC and LipNAC protected the lung with the effects in significantly reducing the increases in transpulmonary albumin flux, neutrophil influx and myeloperoxidase in the lungs of shock/LPS rats. Acetylcysteine 39-42 myeloperoxidase Rattus norvegicus 184-199 27405831-5 1995 In contrast, NAC pretreated rats given paraquat had the same lung lavage CINC levels and lung tissue MPO activity as saline-pretreated rats given paraquat. Acetylcysteine 13-16 myeloperoxidase Rattus norvegicus 101-104 34213003-10 2021 Histopathological injury score, plasma MPO, AST, ALT, tissue MPO and tissue MDA values were statistically significantly lower in the treatment groups, prominently in the levosimendan and NAS combination group concerning liver histopathological damage. Acetylcysteine 187-190 myeloperoxidase Rattus norvegicus 39-42 34213003-10 2021 Histopathological injury score, plasma MPO, AST, ALT, tissue MPO and tissue MDA values were statistically significantly lower in the treatment groups, prominently in the levosimendan and NAS combination group concerning liver histopathological damage. Acetylcysteine 187-190 myeloperoxidase Rattus norvegicus 61-64